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Abstract
Antibiotic resistance has been on the rise and poses major threats to public health.
Bacteria develop multidrug resistance through various mechanisms such as mutated or
modified antibiotic target site, modification of antibiotic molecules, reduction of antibiotic
penetration through bacterial cell membranes and extrusion of drug molecules by efflux
pumps. Increasing evidence indicates that antibiotic permeability is a major barrier
hindering microbial control. However, a robust and rapid screening method to
quantitatively determine the penetration of candidate agents through bacterial
membranes is still missing. To address this challenge, we recently developed a high
throughput method for quantifying membrane penetration of Gram-negative bacteria by
optimizing treatment conditions to lyse the inner and outer membranes separately. In this
study, we further improved the assay throughput and evaluated the penetration of
ciprofloxacin (CIP) and tobramycin (TOB) into Escherichia coli MG1665 and
Pseudomonas aeruginosa PAO1. With optimized experimental conditions, it was found
that cytoplasmic membrane is a critical barrier to CIP and TOB penetration in both species
tested. The results were corroborated by P. aeruginosa PAO1 efflux pump mutants. This
new method can be used in future studies to identify novel antimicrobials and inhibitors
of bacterial efflux pumps.
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CHAPTER 1
INTRODUCTION
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1.1 The rising problem of antibiotic resistance
Antibiotic resistance has become one of the most significant global threats to human
health. In the United States alone, more than 2 million people suffer from bacterial
infections caused by antibiotic-resistant strains each year (Blair, Webber, Baylay, Ogbolu,
& Piddock, 2015). P. aeruginosa is one of the typical strains that can adapt abilities
against antibiotic treatment rapidly through mutation. It is highly acceptable to different
environments so often can be found in vegetables, foods, as well as drinking water.
Infections associated with P. aeruginosa are often life-threatening and difficult to cure due
to the limitation of susceptible antimicrobial agents (Carmeli, Troillet, Eliopoulos, &
Samore, 1999) (Garner, Jarvis, Emori, Horan, & Hughes, 1988). In 2013, Multi-drug
resistant Gram-negative bacteria, including Pseudomonas, were identified as major
pathogens by U.S. Centers for Diseases Control and Prevention (Prevention, 2013). In
2016, the first death on the U.S. due to superbug infection was reported (Christensen &
Goldschmidt, 2016), where a patient showed a rare case of E. coli infection, which
showed resistance to all 26 tested antibiotics. Multiple factors have been found
contributing to antibiotic resistance, including the overuse of antibiotics, as well as failed
patient compliance of antibiotic treatment. Besides, antibiotics kill bacteria by targeting
growth-related targets and thus have intrinsic disadvantages in killing dormant or slowgrowing bacterial cells such as those in biofilms, presisters, and viable but non-culturable
cells (Ayrapetyan, Williams, & Oliver, 2018). Therefore, it is urgent to develop new
molecules to better control infections.
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1.2 Significances of Gram-negative Bacteria
The emergence and spread of multidrug resistance in Gram-negative bacteria are
threatening public health. Currently, more than 80% of severe bacterial clinical infections
are caused by multidrug-resistant Gram-negative bacteria (Chopra, Hawkey, & Hinton,
1992; Du et al., 2018; Fraimow & Tsigrelis, 2011; Nikaido, 1989; Viale, Giannella,
Tedeschi, & Lewis, 2015). Different from Gram-positive bacteria, Gram-negative species
such as E. coli, P. aeruginosa and Salmonella spp., are characterized by the presence of
an outer membrane containing lipopolysaccharide and a periplasm space. The complex
structure of Gram-negative bacteria often protects bacteria from damaging substances
and outside environment. One of the unique features of Gram-negative bacteria is the
presence of an outer membrane, which renders Gram-negative bacteria more resistant
to lipophilic and amphiphilic inhibitors, such as detergents, antibiotics, and
chemotherapeutic agents compare to Gram-positive bacteria (Nikaido, 1996). As a result,
antibiotics are generally facing more challenges to penetrate Gram-negative membranes.
To address this challenge, we developed a new method, which allows the study of drug
accumulation levels between different layers of Gram-negative species to enable high
throughput screening of drug penetration to Gram-negative cells.
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1.3 Platforms of antibiotic discovery
Antibiotics available to date are either natural compounds produced by microbes or
synthetic compounds based on the modification of existing antimicrobials. Most of the
currently used antibiotics were discovered between 1940s and 1960s. The first antibiotic,
penicillin was discovered from an accidental experiment. The Sottish scientist Alexander
Fleming accidentally left a petri dish containing Staphylococci open, and the petri dish
was contaminated by blue-green molds. He observed an inhibited growth around the area
that has been contaminated by the mold so that he discovered penicillin. Later on, Selman
Waksman and his students estabilshed a screening method called the ‘Waksman
platform’. The ‘Waksman platform’ adapted the idea from the discovery process of
penicillin by Alexander Fleming (Fleming, 1929) but more schematically and simply. In
this platform, soil-derived streptomycetes were tested for antimicrobial activity by the disk
diffusion test on an overlay plate (Schatz, Bugie, & Waksman, 2005). The screening of
streptomycetes led to the discovery of the first aminoglycoside, streptomycin. The
‘Waksman platform’ earned Selman Waksman a Nobel prize. In the following 20 years,
the method has been widely adopted in pharmaceutical companies led to mass
production of major classes of antibiotics. Meanwhile, fluoroquinolones were discovered
by the modification of existing compounds. However, after the 1970s, there was no new
class of broad-spectrum agents discovered (Lewis, 2013).

In the 1990s, multiple platforms were developed aiming to discover new sources of
antibiotics, such as using ‘high-throughput screening’ to identify lead compounds for
development and studying the three-dimensional structure of existing compounds for
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‘rational drug design’ (Lewis, 2013). Unfortunately, the efforts failed due to the difficulties
of targeting compounds that can efficiently penetrate the cell membrane. Thus, it is urgent
to develop a capability to identify compounds that can effectively penetrate bacterial
membranes, especially those of Gram-negative species.

1.4 Antibiotic killing mechanisms
Conventional antibiotics kill bacteria by inhibiting a wide range of targets (Walsh, 2003).
Based on the outcome of treatments, antibiotics can be divided into two categories:
bactericidal drugs that kill cells and bacteriostatic drugs that inhibit cell growth. (Pankey
& Sabath, 2004). There are multiple significant antimicrobial drug-target interactions such
as DNA replication, DNA repair, protein synthesis as well as cell wall synthesis (Kohanski,
Dwyer, Hayete, Lawrence, & Collins, 2007; Walsh, 2000). However, we still have limited
understanding of certain primarily antimicrobial drug-target responses and interactions
(Davis, 1987; Drlica & Zhao, 1997; Kohanski et al., 2007; Lewis, 2000). This project aims
to optimize and validate a new screening method developed in our lab for identifying
structural elements that promote membrane penetration. Various antimicrobials are
tested in this study, including ciprofloxacin, tobramycin, and tetracycline.

Ciprofloxacin is a bactericidal drug that belongs to the fluoroquinolone family. Similar to
other fluoroquinolones, it inhibits DNA gyrase (LeBel, 1988). DNA gyrase is a bacterial
enzyme essential to DNA coiling (Reece & Maxwell, 1991). By binding to DNA gyrase,
ciprofloxacin can result in DNA double-strand breakage, which eventually leads to cell
death. Tobramycin is also a bactericidal antibiotic. It binds to the ribosome of bacterial
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cells. As a result, the 70S complex cannot be formed so that the translation cannot occur
(G. Yang, Trylska, Tor, & McCammon, 2006). Tetracycline is a bacteriostatic antibiotic. It
passively diffuses through hydrophilic pores into the outer membrane, and then by an
energy-dependent active transport to pass the inner membrane into the cytoplasmic
space (Chopra et al., 1992; Piédrola Angulo, 2001; Roberts, 1996). By using efflux pump
mutants of P. aeruginosa PAO1, we examined factors that can affect drug penetration
and accumulation.

1.5 Importance of Gram-negative bacteria membrane barriers
As mentioned in the previous section, different from Gram-positive bacteria, Gramnegative bacteria contain two cell membranes: an inner membrane or cytoplasmic
membrane and outer membrane. Previous studies have found that the outer membrane
is directly involved in the intrinsic resistance of Gram-negative bacteria to antimicrobial
agents (Hancock, 1987, 1997; Nikaido, 2003). The outer-membrane barrier has narrow
pores, which act as matrixes to slow down or prevent drug penetration (Nikaido & Vaara,
1985). The low fluidity of the lipoprotein reduces the rate of transmembrane diffusion of
lipophilic solutes (Plésiat & Nikaido, 1992). Thus, the efficiency of antibiotic treatment is
reduced dramatically in the presence of outer membranes.

Besides the double-layer structure, efflux systems are well documented for in the intrinsic
antibiotic resistance. (Lewis, 1994; Ma, Cook, Hearst, & Nikaido, 1994). As demonstrated
by Nikaido et al. (Nikaido, 1989), due to the large surface-to-volume ratio of bacteria cells,
antibiotic penetration through the outer membrane often achieves the equilibrium rapidly.
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For example, the periplasmic layer can reach equilibrium of its external concentration
within 10 to 30 seconds in P. aeruginosa and even more instant in E. coli species (Nikaido,
1989). Therefore, additional mechanisms are involved in the intrinsic antibiotic resistance
of Gram-negative mechanism. With a better understanding of resistance mechanisms,
more effective platforms for antibiotic discovery can be developed.

1.6 Efflux assays
Currently, efflux assays rely on the measurement of fluorescence intensity either by
monitoring the penetration of fluorescent dyes or by characterizing intracellular
conversion of fluorescent products (Figure 1). One type of efflux assay is to introduce a
traceable non-fluorescent component into living cells, which converted to a fluorescent
product after entering the cell (Figure1-A) (Dreier & Ruggerone, 2015). For example,
Alamar Buleâ is a blue colored, non-fluorescent resazurin dye. The present of
oxidoreductase in bacterial cells reduces resazurin to red-fluorescent resorufin, which can
be detected by microscope (Gonzalez & Tarloff, 2001; Rampersad, 2012). Since
oxidoreductase commonly utilizes NADH, NADPH, and FADH as cofactor, it is commonly
used to label live cells. This method also has been used to monitor bacterial growth.
However, this dye does not work well in P. aeruginosa since it is a substrate of MexB
(Vidal-Aroca, Meng, Minz, Page, & Dreier, 2009). Fluorescein-di-b-D-galactopyranoside
(FDG) is another good candidate for tracing non-fluorescent components. FDG could be
hydrolyzed by b-galactosidase to produce fluorescein, which is a common fluorescent
tracer (Fieldler & Hinz, 1994; Russo-Marie, Roederer, Sager, Herzenberg, & Kaiser, 1993;
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N. C. Yang & Hu, 2004). However, current research only indicated that FDG can be
hydrolyzed by E. coli strains, not P. aeruginosa, limiting its application.

The second type of efflux assay adapted the idea of using fluorescent dye as a probe to
characterize bacterial membrane potential and membrane integrity (Figure 1-B). From the
physicochemical properties of fluorescent dye, the information of the efflux pump
mechanism in terms of substrate recognition could be understood (Dreier & Ruggerone,
2015). For example, N-phenyl-1-naphthylamine (NPN) is a substrate of MexB in P.
aeruginosa and AcrB in E. coli (Lomovskaya et al., 1999; Ocaktan, Yoneyama, & Nakae,
1997; Sedgwick & Bragg, 1996); since NPN can penetrate the phospholipid membrane,
the fluorescence signal can be detected when the outer membrane structure is disturbed
(Loh, Grant, & Hancock, 1984; Lomovskaya et al., 1999; Vaara, 1992). Therefore, the
efflux activity can be detected by monitoring the flux of fluorescent dyes.

In addition, liquid chromatography-mass spectrometry (LC-MS) or high-performance
liquid chromatography (HPLC) can be applied to cell lysates to quantify molecule
penetration and thus efflux activity. However, it requires separations of intracellular
components from extracellular substances; and, thus, can be applied to high throughput
assays. In comparison, we developed a new method that allows quantification of the
concentration of candidate molecules in the periplasm and cytoplasm spaces of Gramnegative bacteria in a high throughput manner.
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In the past decays, increasing evidence showed that the active efflux by Gram-negative
bacteria significantly contributes to antibiotic resistance (Levy, 1992; Nikaido, 1994).
Considering the critical role of efflux mechanism in antibiotic resistance in P. aeruginosa,
it is necessary to study the role of efflux pump as well as each part of the efflux pump that
controls the drug accumulation during antibiotic treatments. By studying the specific efflux
systems, this assay can provide new information to guide a rational design of the nextgeneration antimicrobials.

Figure 1. Schematic representation of efflux assays. (A) Introducing non-fluorescence, traceable product
into living cells. The non-florescent product (light pink) increases becomes florescent upon internalization
and interaction with cellular products (dark pink), efflux of the probe (double arrows) decreases internal
florescence intensity and efflux inhibition increases the internal florescence intensity. (B) Introducing
florescence probe into live cells. The florescence probe (dark pink) decreases its florescence intensity
upon interaction with cellular products. Efflux of the probe (double arrows) increases internal florescence
intensity and efflux inhibition decreases the internal florescence intensity. (C) Introducing intracellular
convertible probe into live cells. The product can be enzymatically converted into a florescent product.
Efflux of the intact probe (double arrows) slows down the production, so the internal florescence intensity
decreases, and efflux inhibition increases the internal florescence intensity by increasing the rate of
product formation.
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1.7 P. aeruginosa Efflux Pumps
The last few decays have witnessed a rapid increase in antibiotic resistance, which is
now a well-recognized global threat to public health. P. aeruginosa is a major Gramnegative bacterium frequently involved in infections such as urinary tract infections,
bloodstream infections, and surgical site infections (Dreier & Ruggerone, 2015; Jones,
Stilwell, Rhomberg, & Sader, 2009; Zhanel et al., 2010). One major factor that contributes
to P. aeruginosa multi-drug resistances is the low membrane permeability (Nakae,
Nakajima, Ono, Saito, & Yoneyama, 1999). Molecular genetic evidence also suggests
that the efflux pumps in Gram-negative bacteria are strategies developed through
evaluation for survival in harsh environments (Du et al., 2018). To date, six families of
bacterial efflux pumps have been identified (Figure 2), including: 1. ATP-Binding Cassette
(ABC) family; 2. Major Facilitator Superfamily (MFS); 3. Small Multidrug Resistant (SMR)
family; 4. Multidrug and Toxin Extrusion (MATE) family; 5. Resistance-Nodulation-Cell
Division (RND) superfamily; and 6. Proteobacterial Antimicrobial Compound Efflux
(PACE) family. This study is mainly focused on the RND efflux pump family. The RND
pump contains three components: the outer membrane channel, assembled by three
monomers, located in the inner membrane and overhung into the periplasm space (Dreier
& Ruggerone, 2015; Murakami, Nakashima, Yamashita, Matsumoto, & Yamaguchi, 2006;
Murakami, Nakashima, Yamashita, & Yamaguchi, 2002). The outer membrane channel
contains three monomers, connecting the periplasmic space with the outside (Du et al.,
2018). The adaptor protein completes the efflux system spanning across the inner
membrane, periplasmic space, and outer membrane (Dreier & Ruggerone, 2015). P.
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aeruginosa efflux pumps known to date, and their corresponding antibiotic substrates are
summarized in Table 1. In this study, we adapted our method to further investigated the
drug accumulation level for each efflux components mutant from P. aeruginosa PA14
mexB oprM with ciprofloxacin treatment, P. aeruginosa PAO1 mexC, mexD, oprJ with
Tetracycline as well as P. aeruginosa PAO1 mexY and oprM with tobramycin.

Figure 2. Schematic of Gram-negative bacterial efflux pumps.
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Table 1. Currently known P. aeruginosa efflux pumps and associated substrates.

Efflux System
Periplasmic
Membrane
Fusion
Protein
(MFP)

MexA

MexC

MexE

MexX

Cytoplasmic
Membrane
Transporter
(RND)

MexB

MexD

MexF

MexY

Reference
Outer
Membrane
Factor
(OMF)

OprM

OpJ

OprN

OprM

Antibiotic and Other components

Aminoglycoside; amphenicols; Betalactams; Chloramphenicol;
Ciprofloxacin; Fluoroquinolo;
Macrolides; Novobiocin; suflonamides;
Tetracycline; Thiolactomycin;
Tigacycline; Trimethoprim; Quinolones;
Sulphamethoxazole;
Biocides/detergents/dyes/HSL/aromatic
hydrocarbons
Trimethoprim; Fluoroquinolo;
Cefpirome; Cefozopran; Tetracycline;
Chloramphenicol; Quinolones;
Macrolide; Ethromycin;
Biocides/detergents/dyes/HSL/aromatic
hydrocarbons
Trimethoprim; Chloramphenicol;
Quinolones; Imipenem;
Fluoroquinolones;
Biocides/detergents/dyes/HSL/aromatic
hydrocarbons
Fluoroquinolones; Beta lactams;
Tetracycline; Aminoglycosides;
Macrolides; chloramphenicol;
Tobramycin

MexJ

MexK

OprM/OpmH

Tetracycline; Ethromycin; Biocides

(MexG)
MexH

MexI

OpmD

Fluoroquinolones; Vanadium

MexV

MexW

OprM

Fluoroquinolones; Tetracycline;
Chloramphenicol; Macrolide

MexM

MexN

OprM

Chloramphenicol; Thiamphenicol

TriA TriB

TriC

OpmH

Triclosan
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(X. Z. Li,
Nikaido, &
Poole, 1995)

(Gotoh et al.,
1998)

(Maseda,
Yoneyama, &
Nakae, 2000)
(Morita, Tomida,
& Kawamura,
2012)
(Chuanchuen,
Murata, Gotoh,
& Schweizer,
2005)
(Aendekerk et
al., 2005)
(Y. Li et al.,
2003)
(Mima, Sekiya,
Mizushima,
Kuroda, &
Tsuchiya, 2005)
(Ntreh, Weeks,
Nickels, &
Zgurskaya,
2016)

CHAPTER 2
MATERIALS AND METHODS
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2.1 Bacterial Strains and Growth Medium
Planktonic E. coli MG1665 and P. aeruginosa PAO1 as well as P. aeruginosa PAO1 efflux
mutants (Stover et al., 2000) (Table 2) were routinely grown Luria-Bertani (LB) medium
(NaCl (10g/L);tryptone (10g/L); yeast Extra (5g/L) dissolve in dH2O then autoclave)
(Sambrook & Russel, 2001). Overnight cultures of both strains were inoculated from
streaked plate made from glycerol stocks. Planktonic E. coli MG1665 was used in this
study because antibiotic accumulation level in this strain has been studied (Richter et al.,
2017) , which provides a positive control for our study.

Table 2. Bacteria strains used in this study

Microorganism
E. coli MG1665

Source
(Parkinson & Houts, 1982)

P. aeruginosa PAO1

(Tseng et al., 2013)

P. aeruginosa PAO1 oprJ mutant
P. aeruginosa PAO1 mexD mutant
P. aeruginosa PAO1 mexC mutant
P. aeruginosa PAO1 oprM mutant
P. aeruginosa PAO1 mexY mutant

University of Washington Manoil Lab
(Stover et al., 2000)
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2.2 Sample preparation
Our method has been validated on antibiotic penetration to stationary phase cells, we
especially interested in the stationary phase cell since stationary phase cells are more
tolerance to antibiotic so we can introduce our test efficiently without damage the cell
membrane. For small amounts of cells (sample volume less than 50 mL), overnight
bacterial (Table 2) cultures were diluted to OD600 of 0.5 in 1mL of phosphate buffered
saline (PBS) (NaCl(8g/L); KCl (0.2g/L); Na2HPO4 (1.44g/L); KH2PO4 (0.24g/L) dissolve in
dH2O then adjust to pH=7.4, autoclave) in micro-centrifuge tubes; and then pelleted at
16.1 relative centrifugal force (rcf) for 3 minutes at room temperature. After the
supernatant was discarded, the pellets were washed three times with 1X PBS (NaCl(8g/L);
KCl (0.2g/L); Na2HPO4 (1.44g/L); KH2PO4 (0.24g/L) dissolve in dH2O then adjust to
pH=7.4, autoclave) and re-suspended in equal volume of 1X PBS. Two hundred ug/mL
selected antibiotic was added to each sample. The samples treated with antibiotic were
then incubated at 37°C with shaking at 200 rpm for 15 minutes. Untreated cells were
washed and incubated under the same condition as controls. Immediately after incubation,
cells were pelleted at 16.1 rcf for 3 minutes and washed once with 1X PBS. Vortex the
pellets until the smear of pellets appeared on the bottom of the micro-centrifuge tube. At
this point, the cells were ready for lysis. For large amounts of cells (sample volume is
greater than 50 mL), cell (Table 2) overnight culture has been diluted to OD600 of 0.5 in
50mL FalconTM tubes then pelleted at 9600 rcf for 5 minutes at room temperature and the
supernatant was discarded. The pellet was washed three times with 1X PBS and resuspended in 1X PBS. One mL washed cells were transferred into a micro centrifuge tube
for antibiotic treatment. Same treatment condition described above was followed.
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2.3 Preparation of cell lysates
Our new method was inspired by Gram Staining, which is distinguishes Gram-positive
and Gram-negative bacteria. The decolonization step of Gram Stain uses alcohol/acetone
as to wash away the crystal violet from Gram-negative cells by lysing the outer
membranes. The inner membrane remains intact in this treatment due to the presence of
peptidoglycan (Coico, 2001). In our new penetration assay, we use acetone: ethanol
(vol:vol=1:1) solution lyse the outer membrane and release drug molecules from the
periplasm for quantification. Meanwhile, the whole cell was lysed using chloroform to
quantify the total concentration. The difference between the two will inform the
concentration in the cytoplasm. This process is summarized in Figure 3.

To lyse the outer membrane without damaging the inner membrane, the treatment
time needs to be optimized. One hundred uL acetone/ethanol (1:1=vol:vol) solution was
added to a micro-centrifuge tube (or 100 uL in a well of 96 well plate, see section 2.9) that
contained cell pellet. The sample was mixed by pipetting up and down for 10 seconds.
Then the cell debris was removed by filtering the mixture through 96-well filter plates using
vacuum manifold (0.2um in diameter; Pallâ Corporation, New York, USA) and collecting
the filtered solution with a microfuge tube.

To lyse the whole cell, 100 uL chloroform was added to each microfuge tube
containing re-suspended cell pellet. After gentle mixing of the solution, the sample was
then centrifuged at 5000rpm for 5 minutes. The supernatant was collected using a and
vacuum dried overnight (or ³12 hours).
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Figure 3. Schematic illustration of antibiotic penetration and cell lysing procedures
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2.4 Determining antibiotic concentration using reporter strains.
All cell lysates containing antibiotics released from the periplasm fraction and whole cell
were analyzed to determine the antibiotic concentration using planktonic P. aeruginosa
PAO1 in exponential phase as reporter. Briefly, 1 mL of an overnight culture of P.
aeruginosa PAO1 was diluted with 100ml fresh LB broth and grown at 37°C with shaking
at 200rpm to an OD600 of 0.3. The bacterial cells were then concentrated to OD600 of 0.5
and pelleted at 16.1 rcf for 3 minutes at room temperature. The pellet was washed three
times with 1X PBS and re-suspended in 1X PBS. The lysate was suspended in 100 ul 1X
PBS by vortexing for 5 minutes and added to 1 mL of reporter strains. The samples were
then incubated at 37°C with shaking at 200 rpm for 1 hour, followed by pelleting at 13.2
rpm for 3 minutes and washing twice with 1X PBS to remove the antibiotic that did not
penetrated the cells. Finally, the pellets were re-suspended into 1XPBS. Viable cells were
quantified using the drop plate method (Herigstad, Hamilton, & Heersink, 2001). CFU
were counted after overnight incubation at 37°C. The killing was determined based on
CFU results, which was used to calculate the concentration of antibiotic by fitting a
standard curve (established by treating reporter cells with known concentrations of
antibiotic spike in cell lysates).
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2.5 Optimizing experimental conditions
Temperature Increased experimental temperature may alter the metabolic activity of the
cells which raise the concern that if the experimental temperature would affect the drug
uptake by gram-negative bacteria. As a comparison to the original protocol conditions
(treated in room temperature), planktonic E. coli cells were treated and lysed followed the
same steps described in section 2.1-2.4 in 37°C incubation room.

Vacuum filtration force. The vacuum force was varied as -5kPa and -10kPa. One drop
(~10 µL) of food color (McCormicâ Neon Assorted Food Color) was added to the
acetone/ethanol (1:1=vol: vol) solution to ease visualization during this test. The
penetration of color was followed as an indicator of filter efficiency.

Filtration of cell lysates. The periplasm samples were filtered by applying a vacuum to
96 well filter plates (Pallâ Corporation). The results were compared with those of
centrifuge to identify the best assay condition. Planktonic E. coli MG1665 cells were
treated and lysed following the same steps described in section 2.1-2.4. For centrifugation
filtration, cells were centrifuged for one minute at 16100 rcf after lysis with
acetone/ethanol (1:1=vol: vol)

Acetone/ethanol (1:1=vol: vol) concentration and treatment duration. To verify that
lysing target cells’ outer membrane with acetone/ethanol (1:1=vol: vol) only lysed the
outer membrane and released the drug molecules from the periplasm space without
disrupting the inner membrane, different lysis times were tested. Planktonic E. coli
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MG1665 cells were treated and lysed following the same steps described in section 2.12.4. A series of dilution was also tested (95%, 75%, and 50%) along with different cell
lysis time (10, 20, and 30 s). To corroborate the results, treated samples were also stained
with live/dead staining for 15 minutes and imaged using an Axio Imager M1 Fluorescence
microscope with a camera (Orca-Flash 4.0 LT; Hamamatsu Photonics, Hamamatsu City,
Japan) by Dr. Huan Gu.

Throughput. To achieve high throughput screening, it is important to conduct the
assays in 96-well plates. In this test, we compared the results using microcentrifuge
tubes and 96-well plates.
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CHAPTER 3
RESULTS
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3.1 CIP penetration.
This assay is designed to control the lysis of the two layers of Gram-negative bacterial
membranes separately and to quantify the concentration of drug molecules in the
periplasm and cytoplasm. Dr. Huan Gu in the Ren lab has obtained preliminary results
demonstrating the feasibility of this approach. Experimental group cells were treated with
ethanol: acetone (1:1=vol: vol) solution, both with and without Ciprofloxacin. Then cells
were both stained with Propidium Iodine (PI) and Sytoâ 9. PI is a typical, red-fluorescent,
nuclear and chromosome counterstain dye used to detect dead cells in a population
because it only penetrates compromised membranes and impermeable to live cells.
Ethanol: acetone (1:1=vol: vol) treatments the outer membrane of the cells, so the PI dye
could easily penetrate the cells’ outer membrane. Sytoâ 9 is a green-fluorescent, nuclear
and chromosome counterstain which can penetrate intact membranes to bind to DNA.
Thus, it can stain all the cells. As showed in Figure 4, the control groups, untreated cells
and cells treated only with CIP are showed green color, which indicated that the cell
membranes remained intact. However, for experimental groups, cell treated with ethanol:
acetone (1:1=vol: vol) solution, the majority of cells showed orange/ orange-red color,
which is the indication that both Sytoâ 9 and PI got into the cells. Thus, the outer
membrane is disrupted by the treatment solution. This result not only directly proved that
the ethanol: acetone (1:1=vol: vol) treatment successfully damaged the cell’s outer
membrane, but also demonstrated treating cells with ethanol; acetone solution only
dissolved the outer membrane, not disrupting the whole cell structure. Besides, since the
majority of CIP treated cells still showed green fluorescence, it is confirmed that the CIP
treatment time and concentration were not enough to damage the cell membrane or
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disrupt the cell structure. In addition, analysis with transmission electron microscopy
(TEM) (Figure 4) showed that only the outer membrane was damaged by ethanol:
acetone (1:1=vol: vol) treatment, whereas the inner membranes and cytoplasm space
stayed intact. Thus, the preliminary data confirmed this method could successfully lyse
the cell membranes and allowed the penetration to be evaluated by membrane lysis with
ethanol: acetone (1:1=vol: vol) treatment with the tested antimicrobial.

Figure 4. Representative TEM (bar=100nm) (above) and fluorescence images (bar-10um) (below)of P. aeruginosa
PAO1 planktonic cells (with or without 1h CIP treatment) before and after Ethanol: acetone (1:1=vol:vol) treatment.
*Data from Dr. Huan Gu
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3.2 Confirmation of experimental parameters
3.2.1 Effects of temperature on CIP penetration in E. coli MG1665 cells.
It has been shown by Hajdu et al. (Hajdu et al., 2010) that an increase in temperature can
significantly alter several antimicrobial activities, including tigecycline, daptomycin,
fosfomycin, and cefamandole, in Staphylococcus aureus. The majority of microorganisms
have preferred growth temperature in the range between 25°C to 40 °C (Murray et al.,
2003). In this study, to eliminate artifacts that may affect experimental results, a
temperature control experiment has been performed. Our results indicated that
performing an experiment at different temperatures had impact on the experimental
results (Figure 5). Therefore, it is crucial to perform a screening assay under a controlled
environment. Thus, our future analysis has been performed under room temperature (2325 °C)
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Figure 5. Temperature dependent CIP treatment - E. coli MG1665
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3.2.2 Optimizing the filtration.
To ensure the lysis of outer membrane does not affect the integrity of inner membrane, it
is important to remove acetone and ethanol quickly after the treatment. From a visual
inspection of the colored solutions, higher filtration force acetone: ethanol (vol: vol=1:1)
mixture went through the filter quicker (Figure 6). Thus, the higher vacuum force was
preferred with the purpose of control the cell lysing time. Also, we observed that the
diluted treatment solution required a more extended time pass through the filter.
Therefore, to optimize the periplasmic membrane lysing time, it is necessary to use the
undiluted solution for treatment.
A.

B.

Figure 6. A series of photos of Acetone/ Ethanol solutions with different concentration filtered by different
vacuum force. Purple dye represents 100% Acetone/ethanol (1:1=vol:vol) mixture; Blue dye represents –
95% Acetone/ethanol (1:1=vol:vol) mixture. Low Vacuum Force Filtration via 96 wells plate filter (-5kPa in
Hg) (A); and High Vacuum Force Filtration via 96 wells plate filter (-10kPa in Hg) (B)
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3.2.3 96 well filter plate is the best purification method to prepare periplasmic
lysate.
As described in the previous section, extended outer membrane lysis time may result in
a disruption of the inner membrane structure. Different separation methods (filtration vs.
centrifugation) were tested to optimize the protocol. For the cell lysate after acetone:
ethanol treatment, periplasm lysate collected by centrifugation contained more released
antibiotic compared to the one filtered through the filter plate. This is expected since the
cells remained in contact with the lysing agents during centrifugation and thus may have
partial lysis of inner membranes. In comparison, 96 wells filter plates provided a more
rapid separation, which was more suitable for a high-throughput screening system (Figure

CFU/mL

7).
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Figure 7. Relative antibiotic activities of cell lysates collected by centrifugation and filtration.
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3.2.3 Effects of lysis time.
Another parameter that needs to be optimized is the lysis time for releasing antibiotic
molecules in the periplasm space. Figure 8 indicates, more cell was killed by cell lysates
collected from 20 seconds and 30 seconds lysing groups, thus,10-second cell-lysing time
is effective without damaging the inner membrane. Besides, compared the 30- and 20seconds’ lysate to whole cell lysate, the viable cell number validated the inner cell
membrane was being disrupted with more than 20 seconds’ cell lysing time. Thus, 10
seconds was chosen as the lysis time for incubation with 100% acetone: ethanol (1:1=vol:
vol) solution.
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Figure 8. Effects of lysis time on antibiotic release

In addition, to enable high-throughput screening, we aimed to lyse cells’ outer membranes
in 96 well plates. Figure 9 indicated that using 96 well plate for acetone: ethanol (1:1=vol:
vol) treatment has no significant difference (less than 1% variation in cell surviving rate)
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compared to treat cells in microfuge tubes. Lysing cells in 96 well plates are more scalable
to allow screening and tests with more repeats.
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Figure 9. The lysis protocol can be adapted to assays using 96-well plates.
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3.4 Qualification of antibiotic concentrations in cytoplasm and periplasm
3.4.1 The method to determine antibiotic concentration in the periplasm or
cytoplasm
The concentration of antibiotics can be determined by fitting the CFU of reporter strain
with standard curves of the same strained treated with known concentrations of antibiotics.
The volumes of periplasm and cytoplasm can be estimated based on the average size of
Gram-negative bacteria cells; the average length of bacterial cells (lw) is 3µm; the radium
of bacteria cells (rw) is 1µm, and the thickness of the peptidoglycan layer (rw-rc) is 20nm
(Figure 10).

rw
rc

Lc
Lw
Figure 10. Dimension of Gram-negative cells used in calculation.

Therefore, the following equation was used to estimate the volume of each cell fractions,
where Vw represents the whole cell volume; Vc represents the volume of the cytoplasmic
space, and Vp is the volume of the periplasm space.
Vw = !*rw2*Lw (Equation 1)
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Vc = !*rc2*Lc (Equation 2)
VP = Vw-Vc (Equation 3)
Thus, the concentration of antibiotic accumulated in the periplasm space [P] of the cell
can be calculated as:
[P] = CFU

Xp*1ml
CTL*4.5ml

*Vp

(Equation 4)

Where Xp represents the concentration of antibiotic isolated from 10ml of the periplasm
lysate.
Followed the same idea, the concentration of antibiotic accumulated in the whole cell [W]
can be calculated as:
[W] = CFU

Xw*1ml
CTL*4.5ml

*Vw

(Equation 5)

Where Xw is the concentration of antibiotic isolated from 10ml of the whole cell lysate. The
concentration of antibiotic accumulated in the cytomplasmic space can be calculated by
substracting [P] from [W].
Since we can easily obtain a linear regression from a developed standard curve with
lysate controls, we can calcuate Xw and Xp from the linear regression.
Yw = aw *exp(bw*X) => [Xw] in ug/mL (Equation 6)
Yp = ap *exp(bp*X) => [Xp] in ug/ml (Equation 7)
[Xc] = [XW]-[XP] (Equation 8)
Based on the standard curve, the concentration of CIP in P. aeruginosa PAO1 periplasm
space were estimated to be 107 µg/ml and 0.32µg/ml in cytoplasm space (Table 5). The
stepwise lysis protocol was validate using a reporter assay and LC-MS analysis. LC-MS
is an analytical allows to separation and quantification of compounds in a mixed sample.
Based on Dr. Gu’s preliminary result using reporter strain, there was 92.9ug/ml CIP in the
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periplasm space and 0.2ug/ml CIP in the cytoplasmic space (Courtesy Dr. Huan Gu),
which show consistent result of CIP penetration in P. aeruginosa.
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3.4.2 High level of CIP is accumulated in E. coli MG1665 cells
We also validated our approach by comparing with the LC-MS data of CIP accumulation
in E. coli, as reported by Richter et al. (Richter et al., 2017), Standard curves for
ciprofloxacin quantification were constructed using P. aeruginosa PAO1 as reporter with
the addition of whole cell lysates of E. coli MG1655 (Figure 11). By fitting the standard
curves, we estimated that CIP accumulated in the periplasm and cytoplasm of E. coli
MG1665 cells (Table 4, Figure 13) was 2.78 µg/mL and 2.04µg/ml, respectively. This first
set of validation results were constructed from the average of 10 biological replicates to
demonstrate the repeatability of this assay. In addition, we tested the effect of treating P.
aeruginosa PAO1 cells E. coli MG1665 lysate to ensure there was no artificial effect
(Figure 12).
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Figure 11. Standard killing curve of the reporter strain P. aeruginosa PAO1 by ciprofloxacin. The reporter cells were
harvested from exponential cultures and the treatment was conducted in PBS.
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Figure 12. Reporter strain treated with E. coli MG1665 lysate. Exponential phase P. aeruginosa PAO1 cells were
treated with E. coli MG1665 lysate for 1 hours at 37℃.
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Figure 13. Standard killing curve the reporter strain P. aeruginosa PAO1 treated by released ciprofloxacin from E.
coli MG1665 periplasm lysate (A) and whole cell lysate (B). The reporter cells were harvested from exponential
cultures and the treatment was conducted in PBS.
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Table 3. Quantified concentration of drug accumulation in the periplasm and cytoplasm spaces of E. coli MG1665, P.
aeruginosa PAO1, P. aeruginosa PAO1 efflux pump mutants and P. aeruginosa PA14 efflux pump mutants based on
standard curve established using reporter strain (exponential phase P. aeruginosa PAO1).

Microorganism
E. coli MG1665
P. aeruginosa PAO1
P. aeruginosa PA14 mexB mutant
P. aeruginosa PA14 oprM mutant
P. aeruginosa PAO1
P. aeruginosa PAO1 oprJ mutant
P. aeruginosa PAO1 mexD mutant
P. aeruginosa PAO1 mexC mutant
P. aeruginosa PAO1
P. aeruginosa PAO1 oprM mutant
P. aeruginosa PAO1 mexY mutant
*Data from Dr. Huan Gu

Antibiotic
Used
CIP
CIP
CIP
CIP
TCN
TCN
TCN
TCN
TOB
TOB
TOB
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Periplasm

Cytoplasm

2.04µg/mL
107µg/mL *
77.6µg/mL *
131.9µg/mL *
0.78µg/mL
0.62µg/mL
0.54µg/mL
0.80µg/mL
84µg/mL
169µg/mL
29µg/mL

2.78µg/mL
0.32µg/mL *
7.28µg/mL *
0.02µg/mL *
0.38µg/mL
0.45µg/mL
0.62µg/mL
0.39µg/mL
2µg/mL
11µg/mL
261µg/mL

3.4.3 Cytoplasmic membrane is the major barrier of antibiotic penetration into P.
aeruginosa cells.
Our new assay provides an effective method for understanding bacterial antibiotic
resistance. Periplasm and whole cell lysates from P. aeruginosa PAO1 treated with
200µg/mL ciprofloxacin were obtained and used to treat exponential phase P. aeruginosa
PAO1 reporter strain. Based on the quantified concentration of ciprofloxacin accumulation
in the periplasm and cytoplasm spaces of P. aeruginosa PAO1 cells, the periplasm layer
was found to accumulate more ciprofloxacin (107µg/mL) compared than the cytoplasmic
space (0.32µg/mL) (data from Dr. Huan Gu). To understand if this is limited to CIP, we
also conducted a similar experiment to compare the penetration of tobramycin. From
Tobramycin-P. aeruginosa PAO1 killing curve (Figure 14), we narrowed the linear killing
range with tobramycin concentration up to 100ug/mL. The standard curve for the wild-
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Figure 14. Standard killing curve of the reporter strain P. aeruginosa PAO1 by tobramycin. The reporter cells
were harvested from exponential cultures and the treatment was conducted in PBS.
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type P. aeruginosa PAO1 and its efflux pump mutants with lysate control were tested
(Figure 15).
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Figure15. Standard killing curve the reporter strain P. aeruginosa PAO1 treated by released tobramycin from P.
aeruginosa PAO1 periplasm lysate (A) and whole cell lysate (B). The reporter cells were harvested from exponential
cultures and the treatment was conducted in PBS.

The lysates from P. aeruginosa PAO1 treated with 200µg /mL of tobramycin were
obtained and then used to treat exponential-phase P. aeruginosa PAO1 reporter cells.
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Our data (Table 5 and Figure 15) showed that more tobramycin accumulated in the
periplasm space of P. aeruginosa PAO1 (84µg/mL) compared to the cytoplasmic space
(2µg/mL). This result suggests that the inner membrane of P. aeruginosa PAO1 plays a
critical role in antibiotic resistance.

3.4.4 Antibiotic penetration in efflux pump mutants
Efflux mutants were used in this study to confirm if the inner membrane acts as the main
barrier for drug penetration into P. aeruginosa cells, which also enables us to compare
the roles of each efflux pump system. In this project, we studied P. aeruginosa PAO1
mexY and oprM mutants. MexXY-OprM is an active efflux system known has the
distinctive function to export aminoglycosides, including gentamicin, amikacin,
tobramycin, streptomycin, and neomycin (Hocquet et al., 2003). MexX and MexY together
form tripartite efflux machinery with the outer membrane protein OprM. Therefore, we
investigated the mexX and oprM mutants to test the antibiotic accumulation levels. We
hypothesized that the mexX mutant would have more drugs accumulated in the
cytoplasmic space since mexX is the transporter protein located on the cytoplasmic
membrane. The oprM mutant would have drug accumulated level in the periplasmic
membrane would be impacted since OprM is the outer membrane protein that forms
connections from the periplasmic space to the outside environment.

We first performed the test on wild type P. aeruginosa PAO1 cell. The lysates obtained
from P. aeruginosa PAO1 wild type, P. aeruginosa PAO1 mexX mutant, and P.
aeruginosa PAO1 oprM mutant were treated with 200µg/mL of tobramycin and used to
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treat exponential phase P. aeruginosa PAO1 wild type population. According to the
standard curves (Figure 16 and 17), our data (Table 5) showed that a higher concentration
of tobramycin accumulated in wild type P. aeruginosa PAO1 periplasm space (84µg/mL)
compared to the cytoplasmic space (2µg/mL). Then, we further test the methods as well
as our hypothesis with mutants. When the outer membrane protein channel (oprM) was
mutated, higher concentration of tobramycin was accumulated in the periplasmic space
(169µg/mL) compare to the wild type, which indicated that malfunctioned outer membrane
protein channel could potentially cause in membrane leakage, thus result in a higher drug
accumulation level within the cytoplasmic membrane. Followed by testing the strain has
transport protein (mexY) mutation, the TOB concentration in the cytoplasmic space
(261µg/mL) increased significantly compared to the wild type. Our result demonstrated
that the efflux system has a significant effect on ciprofloxacin and tobramycin penetration.
It also further confirmed that our method could effectively detect the drug penetration in
cytoplasm and periplasm of Gram-negative cells.
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Figure 16. Standard killing curve the reporter strain P. aeruginosa PAO1 treated by released tobramycin from P.
aeruginosa PAO1 oprM mutant periplasm lysate (A) and whole cell lysate (B). The reporter cells were harvested
from exponential cultures and the treatment was conducted in PBS.
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Figure 17. Standard killing curve the reporter strain P. aeruginosa PAO1 treated by released tobramycin from P.
aeruginosa PAO1 mexY mutant periplasm lysate (A) and whole cell lysate (B). The reporter cells were harvested
from exponential cultures and the treatment was conducted in PBS.
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3.4.5 Tetracycline (TCN) has low membrane permeability against P. aeruginosa
PAO1 cells
As described in the previous sections, we have demonstrated that our high throughput
assay can selectively lyse the outer membrane or the whole cell to extract the lysates
with accumulated antibiotics within P. aeruginosa. Consistently, we have shown that the
cytoplasmic membrane is also a major barrier for CIP and TOB penetration. It is well
known that P. aeruginosa PAO1 is less susceptible to TCN treatment in PBS solution (X.
Z. Li et al., 1995) with MIC around 20 µg/mL. Therefore this strain has been chosen as
a negative control to validate this assay. We tested that P. aeruginosa PAO1 is sensitive
to tetracycline when the treatment is performed in LB medium. Therefore, we used
exponential phase P. aeruginosa PAO1 in LB medium as the reporter strain. We
hypothesize that tetracycline has low accumulation in P. aeruginosa cells when the cells
were treated in PBS. To test this hypothesis, the penetration of TCN lysate has been
tested on exponential phase P. aeruginosa PAO1 cells. The killing effect of the reporter
strains was converted to calculate the amount of tetracycline accumulation in the cell
based on the standard curves (Figure 18). With a treatment concentration of 200 µg/mL
of tetracycline, 0.78µg/mL tetracycline was found accumulated in the periplasm space,
and 0.38µg/mL was found in the cytoplasmic space of P. aeruginosa PAO1. In
comparison, 0.62µg/mL and 0.45µg/mL were found accumulated in the periplasm and
cytoplasm of the oprJ mutant, respectively; 0.54µg/ml accumulated in the periplasm
space and 0.62 µg/mL accumulated in the cytoplasmic space of P. aeruginosa PAO1
mexD mutant; and 0.80µg/mL accumulated in the periplasm space and 0.39µg/mL
accumulated in the cytoplasmic space of P. aeruginosa PAO1 mexC mutants (Table 5).
42

Compared to the ciprofloxacin results, tetracycline accumulation in both periplasmic and
cytoplasmic space has been significantly reduced. This is consistent with tetracycline
resistance of P. aeruginosa.
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Figure 18. Standard killing curve the reporter strain P. aeruginosa PAO1 treated by released tetracycline from P.
aeruginosa PAO1 mutant periplasm lysate (A) and whole cell lysate (B). The reporter cells were harvested from
exponential cultures and the treatment was conducted in PBS.
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CHAPTER 4
Discussion
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Multidrug-resistant infection is a significant challenge to human health. (Kraemer,
Ramachandran, & Perron, 2019; Neu, 1992; Wu, Moser, Wang, Høiby, & Song, 2015).
After the discovery of major classes of antibiotics using the ‘Waksman platform’, the pool
of naturally existing antibiotics has become exhausted (Ribeiro da Cunha, Fonseca, &
Calado, 2019). There have only been a few semi-synthesized, and fully synthesized
antibiotics developed based on those naturally occurred drugs. The ‘Waksman platform’
selects lead compounds based on killing activities and does not address penetration. This
platform led to an antimicrobial boom in the 1960s-1980s (Ribeiro da Cunha et al., 2019).
However, this method only provides limited information regarding the mechanism behind
the antibiotic activity. For example, many natural compounds have low efficiency in
penetrate bacterial membranes, especially those of Gram-negative species that have
double-membrane structures. Therefore, it is necessary to develop a method to enable
screening for membrane penetration.

This capability is also needed because the success rate of finding a compound through
screening against P. aeruginosa is 100-fold lower than against Gram-positive species
(Silver, 2011). The permeability of P. aeruginosa outer membranes is approximately only
1-8% of E. coli (Tamber & Hancock, 2004). With the low membrane permeability barriers
and insufficient compound diversity of the screening library to probe this barrier, the
discovery of new antibiotics became extremely challenging (Zgurskaya, Löpez, &
Gnanakaran, 2015). It remains unclear if the extensive studies of E. coli would also apply
to other Gram-negative species. Therefore, our study used P. aeruginosa PAO1 as a
model organism. We demonstrate that not only the outer membrane but also the inner
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membrane of P. aeruginosa plays a critical role in protecting cells from antimicrobial
attack. Based on our result, there were significantly more CIP accumulated in the
periplasmic space of P. aeruginosa PAO1 cells (Table 5). Whereas for the wild-type E.
coli MG1665 cells, a comparable amount of CIP accumulated in the periplasmic and
cytoplasmic space. This observation confirmed that the difference in the membrane
between those two species.

All current studied Gram-negative bacteria have at least one multidrug efflux pump
responsible for antimicrobial resistance (Chang et al., 2015; Nikaido, 2009; Zgurskaya et
al., 2015). The efflux pump, AcrAB-TolC in E. coli, is the best-characterized efflux system.
Numerous studies, including structural and functional analysis of the AcrAB-TolC efflux
pump, has been performed. As indicated by multiple groups, AcrB, a proton-motive force
driven transporter, with the help of AcrA, periplasmic membrane fusion protein, capture
compounds from cytoplasmic and periplasmic spaces and expels them through TolC, the
outer membrane channel(Love, Bhandari, Dobson, & Billington, 2018; Lowy et al., 2010;
Schmelcher, Donovan, & Loessner, 2012). However, there are fewer studies performed
on P. aeruginosa efflux system, especially there are still uncertainties regarding the
mechanism that was corresponding to the functionality of the three-component complex
system.

Our method is able to quantitatively compare the concertation of candidate compounds
in the periplasm and cytoplasm of Gram-negative bacteria separately. Interestingly, P.
aeruginosa PAO1 efflux pump mutants have significantly different drug accumulation
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levels compared to the wild-type strain. To our best knowledge, this has not been studied
before. In this project, we have tested multiple antibiotics with their corresponding efflux
pump component mutants. Under our experimental conditions, we demonstrate that the
efflux transporter protein plays important role in the extrusion of antimicrobial agents. With
the mutation of efflux transporter protein, the accumulation of CIP increased by 20 times,
and TOB accumulation increased 100 times. The result of this study can lead to the
rational design of new molecules with better penetration efficiency.

To achieve high throughput screening, we optimized the protocol by adjusting assay
conditions including temperature, vacuum force, lysing time, and lysate separation. We
take consideration of major environmental factors and performed control experiments
alongside the process of method development. In summary, by optimizing the assay and
comparing different antimicrobials, this study revealed that the inner membrane of Gramnegative bacteria is an essential

barrier for the penetration of ciprofloxacin and

tobramycin; While each of the antibiotic tested here has a different target, we have
observed a higher antibiotic accumulation in the cytoplasmic space of efflux mutants.
These observations are consistent with the critical role of efflux in antibiotic resistance of
Gram-negative bacteria and further validated our new assay method. With all the
validated parameters, this study has been further improved to a high-throughput
screening method for molecules library screening.
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CHAPTER 5
Conclusion and Future Works
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This high throughput assay provides a new capacity to compare the penetration of
selected compounds into Gram-negative cells. The results demonstrated that our highthroughput assay could efficiently quantify the drug penetration in both cytoplasmic and
periplasmic space of various Gram-negative bacteria, including E. coli MG1665, E. coli
K12, P. aeruginosa PAO1, and P. aeruginosa PA14. This assay can be used in future
studies to help design new molecules that can better penetrate the bacterial membranes.
This approach can start with screening of bioactive compound libraries. Currently, more
than 9,000 bioactive compounds with certain antimicrobial and antiviral activities have
been identified (Bérdy, 1984), and some major biomedical companies has commercial
products that offer a broad range of antimicrobials for screening purposes. Such libraries
can pre-screen for killing activities against appropriate reporter strains. After the
identification of reporter strain, the selected library will be tested for compounds that have
better penetration capabilities and identify the important structural elements. Thus, by
using this high throughput assay to screen compound libraries, we can identify more
effective antimicrobial molecules and enable the rational design of next-generation control
agents.
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